Data from a Phase 2b study suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug. Reata Pharmaceuticals and Abbott presented the new findings at the American Society of Nephrology (ASN) Renal Week Conference in Denver, Colorado....